Investors looking for stocks in the Medical - Products sector might want to consider either Prestige Consumer Healthcare (PBH) or Boston Scientific (BSX) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank puts an emphasis on earnings estimates and es ...

Prestige Consumer Healthcare’s (PBH) dedication to brand building drives consistent market share growth. The company has grown its portfolio through internal developments and strategic acquisitions. Investments in online content and digital advertising fuel the company’s e-commerce success. Meanwhile, cost pressures from macroeconomic headwinds and solvency issues weigh on Prestige Consumer’s operations.In the past year, this Zacks Rank #2 (Buy) stock has rallied 27.2% compared with the industry and the S&P ...

Investors with an interest in Medical - Products stocks have likely encountered both Prestige Consumer Healthcare (PBH) and Abbott (ABT) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings es ...

Financial Data and Key Metrics Changes - Q2 sales were $284 million, a slight decline from the prior year due to supply chain limitations for Clear Eyes and timing issues in Q1 [7][16] - Gross margin improved sequentially and remained stable compared to the prior year, with EPS of $1.09, up slightly from the previous year [8][16] - Free cash flow reached $68 million, growing double digits year-over-year, enabling capital deployment for shareholder value enhancement [9][24] Business Line Data and Key Metrics Changes - The International segment and Hydralyte brand showed strong growth, offsetting declines in the eye and ear care category due to Clear Eyes supply constraints [7][16] - The Canadian business represented about 5% of annual sales, with a sales CAGR of approximately 4% since fiscal '20, driven by strong brand performance [10][11] Market Data and Key Metrics Changes - North America segment revenues decreased 3.7%, while International segment revenues increased 4.8% year-over-year [18] - E-commerce accounted for about 15% of overall business, primarily driven by North America [48] Company Strategy and Development Direction - The company anticipates revenues of $1.125 billion to $1.140 billion for fiscal '25, with organic revenue growth of approximately 1% [27][28] - Strategic improvements in the Clear Eyes supply chain are being implemented to enhance long-term brand growth [34] Management's Comments on Operating Environment and Future Outlook - Management noted heightened business environment uncertainty due to supply chain constraints and inflation, impacting results [5] - There is optimism for sequential improvement in Clear Eyes sales in Q3, with expectations for stabilization in trends [33] Other Important Information - The company reduced debt by $40 million, achieving a leverage ratio of 2.7x while continuing share repurchases [9][25] - The anticipated gross margin for the full fiscal year is approximately 56%, driven by pricing actions and cost savings [21] Q&A Session Summary Question: Update on Clear Eyes and Summer's Eve - Management expects sequential improvement in Clear Eyes sales in Q3 and stabilization of trends [33] - Summer's Eve showed flat sales in Q2, with positive momentum and share gains expected [36] Question: Impact of Drugstore Channel Closures - Management indicated that expected store closures are consistent with recent trends and do not significantly impact their business [38] Question: International Business and Hydralyte - Hydralyte continues to perform well with a strong market share, despite new entrants in the hydration category [41] Question: Cash Flow and Capital Allocation - Strong cash flow allows for share repurchases and potential M&A opportunities, with a focus on reducing leverage [43] Question: Competitive Environment and Pricing - The company does not face the same inflationary pressures as other categories, maintaining stable pricing [45] Question: E-commerce Revenue and Growth - E-commerce currently represents about 15% of revenue, primarily from North America, with plans for international expansion [48] Question: Organic Growth Outlook - Management remains confident in returning to a 2% to 3% growth algorithm in the future [49] Question: Gross Margin Expectations - Continued air freight costs are expected, but management anticipates a return to historical gross margin levels [50]

Prestige Consumer Healthcare (PBH) came out with quarterly earnings of $1.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.07 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medicine distributor would post earnings of $0.86 per share when it actually produced earnings of $0.90, delivering a surprise of 4.65%.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Prestig ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____ to _____ Commission File Number: 001-32433 PrestigeConsumer HEALTHCARE PRESTIGE CONSUMER HEALTHCARE INC. (Exact Name of Registrant as Specified in It ...

Exhibit 99.1 Prestige Consumer Healthcare Inc. Reports Second Quarter and First Half Fiscal 2025 Results ◦ Revenue of $283.8 Million in Q2, Ahead of Outlook ◦ Diluted EPS of $1.09 in Q2, Up 2% Versus Prior Year ◦ Net Cash Provided by Operating Activities of Approximately $125 Million in First Six Months, Up Approximately 13%; Reduced Debt by $75 Million and Repurchased $38 Million Shares Year-to-Date ◦ Reaffirming Full-Year Fiscal 2025 Revenue, Earnings, and Cash Flow Outlook TARRYTOWN, N.Y.--(GLOBE NEWSWIR ...

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our S ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a trend to profit from it is easier said than done. The trend often reverses before exiting the trade, leading to a short-term capital loss for investors. So, for a profitable trade, one should confirm factors such as sound fundamentals, positive earnings estimate revisions, etc. that could keep the momentum in the s ...

Investors interested in Medical - Products stocks are likely familiar with Prestige Consumer Healthcare (PBH) and Stryker (SYK) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highl ...